Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on November 24th, 2015 by Joyce de LangenPharmacovigilance
On 16 April 2014, the new EU Clinical Trial Regulation on medicines for human use was adopted. The purpose of the new Clinical Trial Regulation is to create an environment that is favourable for conducting clinical trials, with the highest standards for patient safety, within the EU. (more…)
Posted on November 23rd, 2015 by Agnieszka FredaPharma R&D
Have you ever tried googling ‘Pharma Industry’? Right after Wikipedia, page after page, you will find various articles referring to ‘Getting High on Fat Profits’, ‘Holding Big Pharma Accountable’. (more…)
Posted on November 23rd, 2015 by David EvansChemistry
In a wide ranging interview, we find out what Reaxys PhD Prize Winner Dr. Hiroyuki Miyamura has been up to: (more…)
Screening Scientific Literature for Adverse Drug Reactions: Relevant for Patient Safety or Just a Time-Consuming Regulatory Obligation?
Posted on November 16th, 2015 by Joyce de LangenPharmacovigilance
An adverse drug reaction (ADR) is defined as any response to a medicinal product which is noxious and unintended. ADRs are a major public health problem, accounting for up to 5% of all hospital admissions and 28% of the emergency visits. Of all hospitalized patients, 5% experience an ADR during the hospitalization (more…)
Posted on November 13th, 2015 by Thibault GeouiPharma R&D
As cases of drug-resistant pathogens multiply, the WHO warns of a “post-antibiotic era.” Designing novel antibiotics, however, remains a scientific challenge because achieving therapeutic efficacy requires painstaking testing of compound properties that often conflict. (more…)
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.